Sean Maduck Sells 18,303 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 18,303 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $60.69, for a total transaction of $1,110,809.07. Following the completion of the transaction, the insider now owns 85,622 shares in the company, valued at $5,196,399.18. This trade represents a 17.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Sean Maduck also recently made the following trade(s):

• On Thursday, January 2nd, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00.

Corcept Therapeutics Stock Up 2.0 %

Shares of Corcept Therapeutics stock traded up $1.10 during trading on Friday, reaching $55.40. 1,439,423 shares of the company traded hands, compared to its average volume of 1,035,462. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $75.00. The company has a 50 day moving average price of $60.34 and a 200-day moving average price of $52.16. The firm has a market capitalization of $5.84 billion, a PE ratio of 43.97 and a beta of 0.58.

Remove Ads

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). The company had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. As a group, equities research analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CORT has been the topic of a number of recent analyst reports. Piper Sandler boosted their price target on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a "buy" rating in a research report on Thursday, January 30th. HC Wainwright reiterated a "buy" rating and set a $115.00 target price on shares of Corcept Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com downgraded shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $99.75.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Performance Advisors LLP bought a new stake in Corcept Therapeutics during the 3rd quarter valued at $25,000. Kestra Investment Management LLC bought a new stake in Corcept Therapeutics during the 4th quarter valued at $27,000. Canada Pension Plan Investment Board bought a new stake in Corcept Therapeutics during the 4th quarter valued at $40,000. National Bank of Canada FI bought a new stake in Corcept Therapeutics during the 4th quarter valued at $42,000. Finally, USA Financial Formulas bought a new stake in Corcept Therapeutics during the 4th quarter valued at $54,000. Institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.